How PIPEs finally unblocked biotech’s funding flows
Pathfinders in Biopharma - En podcast af RBC Capital Markets
Kategorier:
The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been universally welcomed.
